Endotronix & Innovalve
2024
$1.1B
Outcome
Expanding addressable market into heart failure and complex structural interventions.
Edwards Lifesciences
Medical Technology & Structural Heart DiseaseFounded 1958- HQ today: Irvine, California, USA
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
Edwards Lifesciences Acquisitions
4
Major Deals Covered
$2.2B
Disclosed Deal Value
What are Edwards Lifesciences's biggest acquisitions?
Edwards Lifesciences's largest disclosed acquisition here is Valtech Cardio for $690 in 2017. This page covers 4 major deals from 2004 to 2024, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Valtech Cardio ($690)
- First deal
- 2004
- Most recent
- 2024
| Company | Year | Price | Purpose |
|---|---|---|---|
| Percutaneous Valve Technologies (PVT) | 2004 | Undisclosed | — |
| Valtech Cardio | 2017 | Undisclosed | — |
| Harpoon Medical | 2017 | Undisclosed | — |
| Endotronix & Innovalve | 2024 | Undisclosed | — |
- What companies has Edwards Lifesciences bought?
- Major acquisitions by Edwards Lifesciences documented here include Valtech Cardio (2017), Harpoon Medical (2017), Percutaneous Valve Technologies (PVT) (2004) and Endotronix & Innovalve (2024).
- What is Edwards Lifesciences's most recent acquisition?
- The most recent Edwards Lifesciences acquisition documented here is Endotronix & Innovalve, in 2024, for $1.1.
Valtech Cardio
2017
$690M
Outcome
Integrated into fast-growing Transcatheter Mitral and Tricuspid Therapies (TMTT) division.
Harpoon Medical
2017
$250M
Outcome
Advanced clinical development and integration into surgical repair portfolios.
Percutaneous Valve Technologies (PVT)
2004
$155M
Outcome
Highly successful cornerstone of Edwards' multi-billion dollar TAVR franchise.
Edwards Lifesciences's Growth & Acquisition Strategy
Executing a multi-pronged growth strategy encompassing geographic expansion, clinical trial indication expansion into lower-risk and asymptomatic cohorts, breakthrough innovations in transcatheter mitral and tricuspid therapies (TMTT), and strategic tuck-in acquisitions of advanced medtech innovators.
How Edwards Lifesciences Makes Money
Edwards Lifesciences operates a high-margin, highly specialized business model focused on structural heart disease innovations. The company generates revenue primarily through the manufacture and global commercialization of transcatheter heart valves, surgical tissue replacements, and cardiac repair systems. By forging deep clinical partnerships with cardiac surgeons and interventional cardiologists, Edwards secures sticky, high-retention hospital accounts. Substantial reinvestment into rigorous clinical trials (such as the PARTNER trials) creates formidable regulatory and clinical moats, enabling premium pricing and robust operating margins. ongoing investments in next-generation tissue preservation technologies like RESILIA ensure that Edwards maintains technological leadership across all major cardiac surgical and transcatheter treatment modalities worldwide.
Edwards Lifesciences Acquisitions FAQ
What is undefined's general approach to M&A and acquisitions?
undefined pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by undefined?
Transformative transactions in undefined's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does undefined successfully integrate acquired companies?
undefined deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does undefined divest non-core corporate assets?
Yes, undefined periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Edwards Lifesciences
Core profile pages, founders and related research hubs for this company.